Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 14/20 | 0.50 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32667704 | 0.87 | SIGMAR1 (0.56) | SIGMAR1 | |
| SCHEMBL21462427 | 0.83 | DRD2 (0.55) | DRD2HTR1APRMT6DRD4HTR2A | |
| SCHEMBL31612486 | 0.79 | SIGMAR1 (0.71) | DRD2HTR1ASIGMAR1CHRM3DRD4 | |
| SCHEMBL3153554 | 0.79 | SIGMAR1 (0.71) | DRD2HTR1ASIGMAR1CHRM3DRD4 | |
| SCHEMBL7508255 | 0.78 | DRD2 (0.67) | DRD2HTR1ADRD4 | |
| SCHEMBL1259602 | 0.77 | SIGMAR1 (0.71) | SIGMAR1PRMT6 | |
| SCHEMBL21961925 | 0.77 | SIGMAR1 (0.71) | SIGMAR1PRMT6 | |
| SCHEMBL1632938 | 0.77 | PRMT6 (0.61) | SIGMAR1CHRM3PRMT6 | |
| SCHEMBL2868372 | 0.75 | HTR7 (0.62) | DRD2HTR1ASIGMAR1HTR2A | |
| SCHEMBL29823861 | 0.75 | CXCR4 (0.69) | SIGMAR1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028326-A1 | COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF | GLUETACS THERAPEUTICS SHANGHAI CO LTD (CN) | 2026-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028326-A1 | COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF | CDR2, CYC1, CLN6 | DRD2 1201/4885HTR1A 597/4885SIGMAR1 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.